Antares Pharma, Inc. announced that the U.S. Food and Drug Administration has approved TLANDO (testosterone undecanoate), an oral treatment for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. Lipocine licensed the exclusive U.S. commercialization rights for TLANDO to Antares Pharma.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.67% | 25.02B |